Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study
The course of clinical management in chronic myeloid leukemia (CML) often faces a road-block in the form of front-line (imatinib) therapy resistance. Subsequently, several hotspot mutations were clinically validated in the kinase domain (KD) of BCR-ABL1, in deterring imatinib sensitivity and further...
| Główni autorzy: | , , , , , , , |
|---|---|
| Format: | Artykuł |
| Język: | English |
| Wydane: |
Elsevier
2022-01-01
|
| Seria: | Cancer Treatment and Research Communications |
| Hasła przedmiotowe: | |
| Dostęp online: | http://www.sciencedirect.com/science/article/pii/S2468294222001265 |
| _version_ | 1828092057574440960 |
|---|---|
| author | Samya Dey Soumi Basu Shahena Shah Debmalya Bhattacharyya Partha Pratim Gupta Mahasweta Acharjee Susanta Roychoudhury Somsubhra Nath |
| author_facet | Samya Dey Soumi Basu Shahena Shah Debmalya Bhattacharyya Partha Pratim Gupta Mahasweta Acharjee Susanta Roychoudhury Somsubhra Nath |
| author_sort | Samya Dey |
| collection | DOAJ |
| description | The course of clinical management in chronic myeloid leukemia (CML) often faces a road-block in the form of front-line (imatinib) therapy resistance. Subsequently, several hotspot mutations were clinically validated in the kinase domain (KD) of BCR-ABL1, in deterring imatinib sensitivity and further, made targeted by next-generation tyrosine-kinase-inhibitor (TKI) drugs. Identifying KD mutations, occurring even at low frequencies, became pertinent here. Globally, cohorts from different origins were tested and the mutational spectra were mapped to categorize clinical management as well as related pathological features of CML. Moreover, targeted deep sequencing could reveal the mutational landscape more efficiently than the less sensitive Sanger sequencing method. However, no such efforts were reported from Eastern Indian cohorts of imatinib-resistant CML-sufferers. This study assessed a prospective study cohort of imatinib-resistant CML cases from Eastern India. Following dissecting the molecular and clinical parameters, the mutational spectrum was comparatively examined using conventional Sanger and next-generation deep sequencing method. This cohort showed a prevalence of e14a2-p210 variant of BCR-ABL1 and acquired resistance against imatinib, while the disease was mostly confined in its chronic phase. Together with a few common hotspot mutations identified in this cohort, deep sequencing revealed cases with a candidate mutation, otherwise undetermined by Sanger method. Also, cases with a second low frequency mutation were identified upon applying deep sequencing. Along with highlighting a few aspects of CML biology employing an Eastern-Indian cohort, this data could mark the immense importance of deep sequencing to contribute in the clinical management of CML upon front-line therapy resistance. |
| first_indexed | 2024-04-11T06:23:13Z |
| format | Article |
| id | doaj.art-a57c9a4c8b0c48c7b0f88d8930b1ae32 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-04-11T06:23:13Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-a57c9a4c8b0c48c7b0f88d8930b1ae322022-12-22T04:40:30ZengElsevierCancer Treatment and Research Communications2468-29422022-01-0133100635Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort studySamya Dey0Soumi Basu1Shahena Shah2Debmalya Bhattacharyya3Partha Pratim Gupta4Mahasweta Acharjee5Susanta Roychoudhury6Somsubhra Nath7Department of Basic and Translational Research, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, IndiaDepartment of Basic and Translational Research, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, India; Department of Molecular Genetics and Cell Biology, University of Nebraska Medical Center, Omaha, USADepartment of Basic and Translational Research, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, IndiaDepartment of Hemato-oncology, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, IndiaDepartment of Hemato-oncology, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, IndiaDepartment of Basic and Translational Research, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, IndiaDepartment of Basic and Translational Research, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, India; CSIR-Indian Institute of Chemical Biology, CN-06, CN Block, Sector V, Kolkata 700091, IndiaDepartment of Basic and Translational Research, Saroj Gupta Cancer Centre and Research Institute, Thakurpukur, Kolkata, 700063, India; Institute of Health Sciences, Presidency University, Plot No. DG/02/02, Premises No. 14-0358, Action Area-ID, New Town, Kolkata, 700156, India; Corresponding author.The course of clinical management in chronic myeloid leukemia (CML) often faces a road-block in the form of front-line (imatinib) therapy resistance. Subsequently, several hotspot mutations were clinically validated in the kinase domain (KD) of BCR-ABL1, in deterring imatinib sensitivity and further, made targeted by next-generation tyrosine-kinase-inhibitor (TKI) drugs. Identifying KD mutations, occurring even at low frequencies, became pertinent here. Globally, cohorts from different origins were tested and the mutational spectra were mapped to categorize clinical management as well as related pathological features of CML. Moreover, targeted deep sequencing could reveal the mutational landscape more efficiently than the less sensitive Sanger sequencing method. However, no such efforts were reported from Eastern Indian cohorts of imatinib-resistant CML-sufferers. This study assessed a prospective study cohort of imatinib-resistant CML cases from Eastern India. Following dissecting the molecular and clinical parameters, the mutational spectrum was comparatively examined using conventional Sanger and next-generation deep sequencing method. This cohort showed a prevalence of e14a2-p210 variant of BCR-ABL1 and acquired resistance against imatinib, while the disease was mostly confined in its chronic phase. Together with a few common hotspot mutations identified in this cohort, deep sequencing revealed cases with a candidate mutation, otherwise undetermined by Sanger method. Also, cases with a second low frequency mutation were identified upon applying deep sequencing. Along with highlighting a few aspects of CML biology employing an Eastern-Indian cohort, this data could mark the immense importance of deep sequencing to contribute in the clinical management of CML upon front-line therapy resistance.http://www.sciencedirect.com/science/article/pii/S2468294222001265Chronic myeloid leukemia (CML)BCR-ABL1Imatinib resistanceKinase domain (KD) mutationNext generation sequencing (NGS) |
| spellingShingle | Samya Dey Soumi Basu Shahena Shah Debmalya Bhattacharyya Partha Pratim Gupta Mahasweta Acharjee Susanta Roychoudhury Somsubhra Nath Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study Cancer Treatment and Research Communications Chronic myeloid leukemia (CML) BCR-ABL1 Imatinib resistance Kinase domain (KD) mutation Next generation sequencing (NGS) |
| title | Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study |
| title_full | Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study |
| title_fullStr | Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study |
| title_full_unstemmed | Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study |
| title_short | Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study |
| title_sort | deep sequencing reveals the spectrum of bcr abl1 mutations upon front line therapy resistance in chronic myeloid leukemia an eastern indian cohort study |
| topic | Chronic myeloid leukemia (CML) BCR-ABL1 Imatinib resistance Kinase domain (KD) mutation Next generation sequencing (NGS) |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222001265 |
| work_keys_str_mv | AT samyadey deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy AT soumibasu deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy AT shahenashah deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy AT debmalyabhattacharyya deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy AT parthapratimgupta deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy AT mahaswetaacharjee deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy AT susantaroychoudhury deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy AT somsubhranath deepsequencingrevealsthespectrumofbcrabl1mutationsuponfrontlinetherapyresistanceinchronicmyeloidleukemiaaneasternindiancohortstudy |